US Food and Drug Administration Approval of Addyi (Flibanserin) for Treatment of Hypoactive Sexual Desire Disorder

mirtazapinemirtazapine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. mirtazapine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

• Direct comparison trials between flibanserin and bremelanotide are lacking.
• Choice of treatment depends on patient preference, risk profile, and cost.
• Psychological and interpersonal factors are important contributors to HSDD.
• Combining medication with sex therapy or counseling may improve outcomes.
• Flibanserin does not increase libido in individuals without HSDD.
• It is not approved or intended for use as a recreational or enhancement drug.
• Off-label use, such as in postmenopausal women or men, is not supported by evidence.
• Healthcare providers must complete an online knowledge assessment for REMS certification.
• Certification must be renewed periodically according to the REMS program.

mitapivatmitapivat decreases levels of flibanserin by affecting hepatic enzyme CYP2C19 metabolism.

Precautions while using flibanserin

micafungin will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Risk for sedation increased if flibanserin is coadministration with other CNS depressants.midazolam will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Concomitant use of barbiturates, alcohol, or other CNS depressants may increase the risk of hypoventilation, airway obstruction, desaturation, or apnea and may contribute to profound and/or prolonged drug effect. mifepristonemifepristone will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. mifepristone will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Monitor patients for loss of therapeutic effect if taking sensitive CYP2C19 substrates.

mitapivat decreases levels of flibanserin by affecting hepatic enzyme CYP2C19 metabolism. mitotanemitotane will decrease the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. mitotane will decrease the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

Reward Processing as a Symptom Dimension in Psychiatric Disorders

lansoprazole will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. larotrectiniblarotrectinib will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. larotrectinib will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Either increases effects of the other by sedation. Dosage adjustment may be necessary if lemborexant is coadministered with other CNS depressants because of potentially additive effects.

SMILES string

lenvatiniblenvatinib will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. lenvatinib will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. lomitapideflibanserin increases levels of lomitapide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Reduce lomitapide dose if coadministered with weak CYP3A4 inhibitors (see Dosage Modifications in drug monograph). flibanserin increases levels of lomitapide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. mitoxantronemitoxantrone will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. mitoxantrone will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. modafinilmodafinil will increase the level or effect of flibanserin by affecting hepatic enzyme CYP2C19 metabolism.

modafinil will increase the level or effect of flibanserin by affecting hepatic enzyme CYP2C19 metabolism.

IN THEIR WORDS

isoniazidisoniazid will increase the level or effect of flibanserin by affecting hepatic enzyme CYP2C19 metabolism. isoniazid will increase the level or effect of flibanserin by affecting hepatic enzyme CYP2C19 metabolism. isradipineisradipine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. isradipine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. istradefyllineistradefylline will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

Related treatment guides

Istradefylline 40 mg/day increased peak levels and AUC of CYP3A4 substrates in clinical trials. This effect was not observed with istradefylline 20 mg/day. Consider dose reduction of sensitive CYP3A4 substrates. istradefylline will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. lansoprazolelansoprazole will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. nafcillinnafcillin will decrease the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

In case of emergency/overdose

lomustinelomustine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. lomustine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. losartanlosartan will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. losartan will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. lovastatinlovastatin will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

Oral Administration

lovastatin will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. lumacaftor/ivacaftorlumacaftor/ivacaftor will decrease the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. lumacaftor/ivacaftor will decrease the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. lurasidonelurasidone will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Increased flibanserin adverse effects may occur if coadministered with multiple weak CYP3A4 inhibitors.flibanserin, lurasidone. nafcillin will decrease the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

naldemedineflibanserin increases levels of naldemedine by P-glycoprotein (MDR1) efflux transporter. Monitor naldemedine for potential adverse effects if coadministered with P-gp inhibitors.

Addyi (flibanserin) contraindications

ginkgo biloba will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. flibanserin will increase the level or effect of glecaprevir/pibrentasvir by P-glycoprotein (MDR1) efflux transporter. glyburideglyburide will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. glyburide will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. hydralazinehydralazine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

Key Takeaways

hydralazine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. ifosfamideifosfamide will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. ifosfamide will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. irbesartanirbesartan will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. irbesartan will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. flibanserin increases levels of naldemedine by P-glycoprotein (MDR1) efflux transporter.

Frequently asked questions

methimazole will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. methoxsalenmethoxsalen will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. methoxsalen will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. methylprednisolone will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. micafunginmicafungin will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. nevirapinenevirapine will decrease the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

• Potential for negative publicity and stigma surrounding a "pink Viagra."
• Media coverage often oversimplifies its mechanism and expected results.
• Patient education is crucial to set realistic expectations about benefits.
• Support groups and online communities exist for women discussing HSDD treatment.
• Ongoing research continues to explore other pharmacologic targets for HSDD.
• Future developments may include new formulations or combination therapies.
• The approval of flibanserin spurred increased investment in female sexual health.
• It remains a subject of debate in medical ethics, women's health, and drug regulation.
• Prescribers should stay updated on post-marketing safety communications.

nevirapine will decrease the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. nifedipinenifedipine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. nifedipine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. nisoldipinenisoldipine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

INDICATION AND IMPORTANT SAFETY INFORMATION INCLUDING BOXED WARNING

lurasidone will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. mavorixaforflibanserin will increase the level or effect of mavorixafor by P-glycoprotein (MDR1) efflux transporter. Monitor mavorixafor if coadministered with P-gp inhibitors and reduce mavorixafor dose if needed. flibanserin will increase the level or effect of mavorixafor by P-glycoprotein (MDR1) efflux transporter. mefloquinemefloquine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

What should I know about Addyi before using it?

mefloquine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. mestranolmestranol will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. mestranol will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Risk for sedation increased if flibanserin is coadministration with other CNS depressants.methadone will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. methimazolemethimazole will increase premature ejaculation pills the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. nisoldipine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. nitrous oxidenitrous oxide and flibanserin both increase sedation.

nitrous oxide and flibanserin both increase sedation. nizatidinenizatidine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism.